◆ NeutralNYXH
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
GlobeNewswire Inc.·
Nyxoah reported Q3 2026 global net revenue of €9.2 million with 29% sequential U.S. growth, but lowered full-year 2026 revenue guidance to €33-35 million from €36-40 million. The company submitted a PMA supplement to expand its Genio hypoglossal nerve stimulation system to Complete Concentric Collapse patients, with the ACCCESS study meeting efficacy endpoints at 77.2% AHI responder rate.
Read Full Article at GlobeNewswire Inc. →